Horn R, Parker M. Opening Pandora's box?: ethical issues in prenatal whole genome and exome sequencing. Prenat Diagn 2018; 38:20.
710 710. Bunnik EM, de Jong A, Nijsingh N, et al. The new genetics and informed consent: differentiating choice to preserve autonomy. Bioethics 2013; 27:348.
711 711. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med 2012; 14:759.
712 712. Committee on Genetics and the Society for Maternal‐Fetal Medicine. Committee opinion no. 682: microarrays and next‐generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol 2016; 128:e262.
713 713. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19:249.
714 714. Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high‐penetrance mutations in cancer‐susceptibility genes. Am J Hum Genet 2012; 91:97.
715 715. Pinxten W, Howard HC. Ethical issues raised by whole genome sequencing. Best Pract Res Clin Gastroenterol 2014; 28:269.
716 716. Committee of the International Huntington Association and the World Federation of Neurology. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994; 31:555.
717 717. International Huntington Association and World Federation of Neurology. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994; 44:1533.
718 718. Skirton H, Goldsmith L, Jackson L, et al. Quality in genetic counseling for presymptomatic testing‐clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet 2013; 21:256.
719 719. MacLeod RTA, Frontali M, Evers‐Kiebooms G, et al. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet 2013; 23:221.
720 720. Tibben A, Duivenvoorden J, Niermeijer MF, et al. Psychological effects of presymptomatic DNA testing for Huntington's disease in theDutch program. Psychosom Med 1994; 56:526.
721 721. Lawson K, Wiggins S, Green T, et al. Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. J Med Genet 1996; 33:856.
722 722. Wiggins S, Whyte P, Huggins M, et al. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med 1992; 327:1401.
723 723. Evers‐Kiebooms G, Nys K, Harper P, et al. Predictive DNA‐testing for Huntington's disease and reproductive decision making: a European collaborative study. Eur J Hum Genet 2002; 10:167.
724 724. Migliore S, Jankovic J, Squitieri F. Genetic counseling in Huntington's disease: potential new challenges on horizon? Front Neurol 2019; 10:453.
725 725. Kenney C, Powell S, Jankovic J. Autopsy‐proven Huntington's disease with 29 trinucleotide repeats. Mov Dis 2007; 22:127.
726 726. Killoran A, Biglan KM, Jankovic J, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 2013; 80:2022.
727 727. Cubo E, Ramos‐Arroyo MA, Martinez‐Horta S, et al. Intermediate CAG repeats in Huntington' s disease. A longitudinal analysis of the European Huntington' s Disease Network Registry Cohort (S25. 003). Neurology 2016; 86:571.
728 728. Kay C, Collins JA, Miedzybrodzka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 2016; 87:282.
729 729. Perry TL. Some ethical problems in Huntington's chorea. Can Med Assoc J 1981; 125:1098.
730 730. Quaid KA, Brandt J, Faden RR, et al. Knowledge, attitude and the decision to be tested for Huntington's disease. Clin Genet 1989; 36:431.
731 731. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001; 69:1385.
732 732. Evers‐Kiebooms G, Swerts A, Cassimann JJ, et al. The motivation of at‐risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet 1989; 35:29.
733 733. Sorenson SA, Fenger K. Suicide in patients with Huntington's disease and their sibs. Am J Hum Genet 1991; 49:316.
734 734. Schoenfeld M, Myers RH, Cupples LA, et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 47:1283.
735 735. Almqvist EW, Bloch M, Brinkman R, et al., on behalf of an International Huntington Disease Collaborative Group. A worldwide assessment of the frequency of suicide, suicide attempts or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999; 64:1293.
736 736. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19:441.
737 737. Kachian ZR, Cohen‐Zimerman S, Bega D, et al. Suicidal ideation and behavior in Huntington's disease: systematic review and recommendations. J Affect Disord 2019; 250:319.
738 738. McGarry A, McDermott MP, Kieburtz K, et al. Risk factors for suicidality in Huntington disease. Neurology 2019; 92:e1643.
739 739. Wesson M, Boileau NR, Perlmutter JS, et al. Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease. J Huntingtons Dis 2018; 7:239.
740 740. Markel DS, Young AB, Penney JB. At‐risk persons' attitudes toward presymptomatic and prenatal testing of Huntington's disease in Michigan. Am J Med Genet 1987; 26:295.
741 741. Lamport AN. Presymptomatic testing for Huntington's chorea: ethical and legal issues. Am J Med Genet 1987; 26:307.
742 742. Taylor CA, Myers RH. Long‐term impact of Huntington disease linkage testing. Am J Med Genet 1997: 70:365.
743 743. Hayden MR. Predictive testing for Huntington disease: are we ready for widespread community implementation? Am J Med Genet 1991; 40:515.
744 744. Nance MA, Leroy BS, Orr HT, et al. Protocol for genetic testing in Huntington disease: three years of experience in Minnesota. Am J Med Genet 1991; 40:518.
745 745. Decruyenaere M, Evers‐Kiebooms G, Cloostermans T, et al. Psychological distress in the 5‐year period after predictive testing for Huntington's disease. Eur J Hum Genet 2003; 11:30.
746 746. Winnberg E, Winnberg U, Pohlkamp L, et al. What to do with a second chance in life? Long‐term experiences of non‐carriers of Huntington's disease. J Genet Couns 2018; 27:1438.
747 747. Gusella JF, McNeil S, Persichetti F, et al. Huntington's disease. Cold Spring Harb Symp Quant Biol 1996; 61:615.
748 748. Kremer B, Goldberg P, Andrew SE. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994; 330:1401.
749 749. Alonso ME, Yescas P, Rasmussen A, et al. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Clin Genet 2002; 61:437.
750 750. Evans DGR, Maher EF, Macleod R, et al. Uptake of genetic testing for cancer predisposition. J Med Genet 1997; 34:746.
751 751. Veldhuisen B, Saris JJ, deHaij S, et al. A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2). Am J Hum Genet 1997; 61:547.
752 752. Deltas CC, Christodoulou K, Tjakouri C, et al. Presymptomatic molecular diagnosis of autosomal dominant polycystic kidney disease using PKD1‐ and PKD2‐linked markers in Cypriot families. Clin Genet 1996; 50:10.
753 753. Pirson Y, Chaveau D. Intracranial aneurysms in autosomal dominant polycystic kidney disease. In: Watson ML, Torres VE, eds. Polycystic kidney disease. Oxford: Oxford University Press, 1996:530.
754 754. Liu D, Wang CJ, Judge DP, et al. A Pkd1‐Fbn1 genetic interaction implicates TGF‐β signaling in the pathogenesis of vascular